Sign In
Buy AXGN
$42.21
+0.86 (+2.08%)
At Close: Jul 31, 2026
AxoGen: Far More Constructive With Q1 Numbers, Profitability The Next Hurdle
02:49am, Friday, 23'rd Jun 2023
AxoGen is showing potential for growth, and management expects a record $160 million in revenue this year. Focus on core and active accounts has yielded positive results, with YoY growth of 23% and 9%
Wall Street Analysts Think AxoGen (AXGN) Could Surge 69.62%: Read This Before Placing a Bet
10:57am, Friday, 09'th Jun 2023
The mean of analysts' price targets for AxoGen (AXGN) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023
04:05pm, Tuesday, 18'th Apr 2023
ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,
Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023
04:00pm, Thursday, 02'nd Mar 2023
ALACHUA, Fla. and TAMPA, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,
Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)
01:50pm, Friday, 11'th Nov 2022 Zacks Investment Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price St
Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)
10:32am, Friday, 11'th Nov 2022
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price St
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
01:15pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AxoGen, Inc. (AXGN) Q3 2022 Earnings Call Transcript
10:40am, Tuesday, 08'th Nov 2022
AxoGen, Inc. (NASDAQ:AXGN ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, CEO & President Pete Mariani - EVP & CFO
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
09:48am, Tuesday, 08'th Nov 2022
AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates
10:35pm, Monday, 07'th Nov 2022 Zacks Investment Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Axogen to Participate at Upcoming Investor Conferences
04:00pm, Thursday, 03'rd Nov 2022
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t
Axogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.
11:00am, Monday, 31'st Oct 2022 GlobeNewswire Inc.
Dr. Tyndall is currently the Executive Vice President for Health Affairs and Dean of Morehouse School of Medicine. Dr. Tyndall is currently the Executive Vice President for Health Affairs and Dean of
AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know
04:00pm, Thursday, 27'th Oct 2022 Zacks Investment Research
AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know
01:32pm, Thursday, 27'th Oct 2022
AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Axogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022
07:00am, Thursday, 20'th Oct 2022
ALACHUA and TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a
